Tandem Diabetes Care Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $21.605
- Today's High:
- $23.77
- Open Price:
- $23.26
- 52W Low:
- $21.605
- 52W High:
- $59.91
- Prev. Close:
- $23.61
- Volume:
- 1736444
Company Statistics
- Market Cap.:
- $1.54 billion
- Book Value:
- 5.06
- Revenue TTM:
- $790.35 million
- Operating Margin TTM:
- -13.43%
- Gross Profit TTM:
- $412.99 million
- Profit Margin:
- -28.4%
- Return on Assets TTM:
- -6.69%
- Return on Equity TTM:
- -57.64%
Company Profile
Tandem Diabetes Care Inc had its IPO on 2013-11-14 under the ticker symbol TNDM.
The company operates in the Healthcare sector and Medical Devices industry. Tandem Diabetes Care Inc has a staff strength of 2,600 employees.
Stock update
Shares of Tandem Diabetes Care Inc opened at $23.26 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $21.61 - $23.77, and closed at $23.26.
This is a -1.48% slip from the previous day's closing price.
A total volume of 1,736,444 shares were traded at the close of the day’s session.
In the last one week, shares of Tandem Diabetes Care Inc have slipped by -16.48%.
Tandem Diabetes Care Inc's Key Ratios
Tandem Diabetes Care Inc has a market cap of $1.54 billion, indicating a price to book ratio of 6.2451 and a price to sales ratio of 3.2869.
In the last 12-months Tandem Diabetes Care Inc’s revenue was $790.35 million with a gross profit of $412.99 million and an EBITDA of $-91298000. The EBITDA ratio measures Tandem Diabetes Care Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Tandem Diabetes Care Inc’s operating margin was -13.43% while its return on assets stood at -6.69% with a return of equity of -57.64%.
In Q2, Tandem Diabetes Care Inc’s quarterly earnings growth was a negative -37% while revenue growth was a negative 2.2%.
Tandem Diabetes Care Inc’s PE and PEG Ratio
- Forward PE
- 1111.1111
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-2.9 per share while it has a forward price to earnings multiple of 1111.1111 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Tandem Diabetes Care Inc’s profitability.
Tandem Diabetes Care Inc stock is trading at a EV to sales ratio of 3.0955 and a EV to EBITDA ratio of -51.9983. Its price to sales ratio in the trailing 12-months stood at 3.2869.
Tandem Diabetes Care Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $946.68 million
- Total Liabilities
- $174.66 million
- Operating Cash Flow
- $5.70 million
- Capital Expenditure
- $9.89 million
- Dividend Payout Ratio
- 0%
Tandem Diabetes Care Inc ended 2024 with $946.68 million in total assets and $0 in total liabilities. Its intangible assets were valued at $946.68 million while shareholder equity stood at $329.23 million.
Tandem Diabetes Care Inc ended 2024 with $0 in deferred long-term liabilities, $174.66 million in other current liabilities, 65000.00 in common stock, $-888837000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $130.75 million and cash and short-term investments were $507.25 million. The company’s total short-term debt was $17,757,000 while long-term debt stood at $284.13 million.
Tandem Diabetes Care Inc’s total current assets stands at $764.30 million while long-term investments were $0 and short-term investments were $376.50 million. Its net receivables were $98.71 million compared to accounts payable of $57.08 million and inventory worth $147.60 million.
In 2024, Tandem Diabetes Care Inc's operating cash flow was $5.70 million while its capital expenditure stood at $9.89 million.
Comparatively, Tandem Diabetes Care Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $23.26
- 52-Week High
- $59.91
- 52-Week Low
- $21.605
- Analyst Target Price
- $42.43
Tandem Diabetes Care Inc stock is currently trading at $23.26 per share. It touched a 52-week high of $59.91 and a 52-week low of $59.91. Analysts tracking the stock have a 12-month average target price of $42.43.
Its 50-day moving average was $29.01 and 200-day moving average was $35.51 The short ratio stood at 5.42 indicating a short percent outstanding of 0%.
Around 59.3% of the company’s stock are held by insiders while 10844.6% are held by institutions.
Frequently Asked Questions About Tandem Diabetes Care Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company’s flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump’s software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.